<html><head><meta http-equiv="Content-Type" content="text/html charset=utf-8"></head><body style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space;" class=""><div class=""><a href="http://keionline.org/node/2308" class="">http://keionline.org/node/2308</a></div><div class=""><br class=""></div><div class=""><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Knowledge Ecology International Leaks TPP Text on Intellectual Property</strong><br class=""><em class=""><br class="">Tuesday, August 4th, 2015</em></div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class="">Today, August 4, 2015, Knowledge Ecology International (KEI) released text from three sections of the 95-page secret negotiating text on the Intellectual Property Chapter being used in the Trans-Pacific Partnership Agreement (TPP, sometimes referred to as TPPA) trade negotiations. The negotiating text is dated May 11, 2015, and reflects the state of the text right before the Maui rounds of the negotiation, which ended Friday, July 31, 2015.</div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class="">Released this morning is text from the following sections of the IP Chapter:</div><ul style="color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><li class="">All of Section B on Cooperation. (Pages 8 to 10 of the IP Chapter)</li><li class="">All of Section E on “Patents / Undisclosed Test or Other Data / Traditional Knowledge.” (Pages 29 to 53 of the IP Chapter)</li><li class="">Articles 1 through 11 from Section H on enforcement. (Pages 67 through 89 of the IP Chapter)</li></ul><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class="">We hope to release the remaining sections (A, C, D, F, G, and the rest of H) later today and Wednesday.</div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class="">The text will be placed on this web page: <a href="http://keionline.org/tpp/11may2015-ip-text" style="text-decoration: none; color: rgb(108, 130, 146);" class="">http://keionline.org/tpp/11may2015-ip-text</a></div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class="">The text released this morning is most relevant to issues related to pharmaceuticals, especially rules on biologics and new chemicals. Later today or tomorrow, KEI will release sections of the text relevant to copyright and trademarks.</div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class="">KEI will publish a more detailed analysis of the text later. James Love, Director of Knowledge Ecology International, released the following statement this morning:</div><blockquote style="color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><div style="margin-top: 0.5em; margin-bottom: 0.5em;" class="">“KEI is publishing the consolidated text for the TPP IP Chapter from May 11, 2015, in order to enable the public to understand, analyze, and influence the rules that have been proposed for intellectual property in this important trade negotiation. Over 600 corporate advisors already have access to this text, and this leak, at least temporarily, levels the field somewhat (there will be a new text coming out of last week’s talks in Maui).</div><div style="margin-top: 0.5em; margin-bottom: 0.5em;" class="">The May 11, 2015, text includes country positions, and reveals extensive disagreements among parties, as well as the isolation of the United States as the country that continues to be the most aggressive supporter of expanded intellectual property rights for drug companies, publishers and other companies.</div><div style="margin-top: 0.5em; margin-bottom: 0.5em;" class="">The proposals contained in the TPP will harm consumers and in some cases block innovation. In countless ways, the Obama Administration has sought to expand and extend drug monopolies and raise drug prices. The astonishing collection of proposals pandering to big drug companies make more difficult the task of ensuring access to drugs for the treatment of cancer and other diseases and conditions.</div><div style="margin-top: 0.5em; margin-bottom: 0.5em;" class="">The widely reported dispute over the number of years of protection for biologic drug test data is only one of dozens of measures that significantly expand the power of big drug companies to charge high prices. Taken together these provisions will take the public down a road of more and more rationing of medicines, and less and less equality of access. It could have and still can be different. Rather than focusing on more intellectual property rights for drug companies, and a death-inducing spiral of higher prices and access barriers, the trade agreement could seek new norms to expand the funding of medical R&D as a public good, an area where the United States has an admirable track record, such as the public funding of research at the NIH and other federal agencies. Many people reading the provisions released today will appreciate how misguided and wrong are the USTR’s values and negotiating objectives.”</div><div style="margin-top: 0.5em; margin-bottom: 0.5em;" class=""><em class="">James Love, Director, KEI, August 4, 2015</em></div></blockquote><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class="">For more information and perspectives, we are also attaching the names and contact information for several persons who can comment on the text released this morning, including health and consumer group NGOs, academics, and industry experts. </div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Health and consumer group NGOs</strong><br class=""><strong class=""><br class="">Knowledge Ecology International</strong><br class="">James Love, Director, +1.202.361.3040, <a href="mailto:james.love@keionline.org" style="text-decoration: none; color: rgb(108, 130, 146);" class="">james.love@keionline.org</a><br class="">Andrew S. Goldman, Counsel for Policy & Legal Affairs, +1.202.332.2670, <a href="mailto:andrew.goldman@keionline.org" style="text-decoration: none; color: rgb(108, 130, 146);" class="">andrew.goldman@keionline.org</a><br class="">Thiru Balasubramaniam, Geneva Representative, <a href="mailto:thiru@keionline.org" style="text-decoration: none; color: rgb(108, 130, 146);" class="">thiru@keionline.org</a>, +41 22 791 6727</div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Public Citizen</strong><br class="">Peter Maybarduk, Director, +1.202.588.7755, <a href="mailto:pmaybarduk@citizen.org" style="text-decoration: none; color: rgb(108, 130, 146);" class="">pmaybarduk@citizen.org</a><br class="">Burcu Kilic, Research Director, +1.202.588.7792, <a href="mailto:bkilic@citizen.org" style="text-decoration: none; color: rgb(108, 130, 146);" class="">bkilic@citizen.org</a></div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Doctors Without Borders/Médecins Sans Frontières</strong><br class="">Judit Rius Sanjuan, U.S. Manager & Legal Policy Adviser, Access Campaign, T: +1.212.655.3762, M: +1.917.331.9077, <a href="mailto:Judit.Rius@newyork.msf.org" style="text-decoration: none; color: rgb(108, 130, 146);" class="">Judit.Rius@newyork.msf.org</a></div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Academics</strong></div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Professor Susan K. Sell</strong><br class="">Elliott School of International Affairs<br class="">George Washington University<br class="">T: (202) 994-4896<br class=""><a href="mailto:susan.sell@gmail.com" style="text-decoration: none; color: rgb(108, 130, 146);" class="">susan.sell@gmail.com</a></div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Professor Kevin Outterson</strong><br class="">Boston University School of Law<br class=""><a href="mailto:mko@bu.edu" style="text-decoration: none; color: rgb(108, 130, 146);" class="">mko@bu.edu</a></div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Dr. Deborah Gleeson</strong><br class="">Department of Public Health<br class="">La Trobe University<br class="">Melbourne, Australia<br class="">T: +61 3 9479 3262<br class="">M: +61 423 209029<br class=""><a href="mailto:deborah@gleeson.net" style="text-decoration: none; color: rgb(108, 130, 146);" class="">deborah@gleeson.net</a></div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Professor Margot Kaminski</strong><br class="">Moritz College of Law<br class="">Ohio State University<br class=""><a href="mailto:margot.kaminski@gmail.com" style="text-decoration: none; color: rgb(108, 130, 146);" class="">margot.kaminski@gmail.com</a></div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Professor Brook K. Baker</strong><br class="">Program on Human Rights and the Global Economy<br class="">Northeastern University School of Law<br class="">T: (617) 373=3217<br class="">M: (617) 259-0760<br class=""><a href="mailto:b.baker@neu.edu" style="text-decoration: none; color: rgb(108, 130, 146);" class="">b.baker@neu.edu</a></div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Dr. Ruth Lopert</strong><br class="">Department of Public Health<br class="">George Washington University<br class="">(202) 415-7726<br class=""><a href="mailto:rlopert@gwu.edu" style="text-decoration: none; color: rgb(108, 130, 146);" class="">rlopert@gwu.edu</a></div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Pharmaceutical and biotechnology industry experts who are familiar with the TPP IP Chapter </strong></div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Joseph Damond</strong><br class="">Senior Vice President, International Affairs<br class="">Biotechnology Industry Organization (BIO)<br class=""><a href="mailto:jDamond@bio.org" style="text-decoration: none; color: rgb(108, 130, 146);" class="">jDamond@bio.org</a></div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Members of USTR’s Industry Trade Advisory Committees (ITAC)</strong></div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class="">ITAC 15: Industry Trade Advisory Committee on Intellectual Property Rights</div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Gregg H. Alton, Esq.</strong><br class="">Executive Vice President, Corporate and Medical Affairs, Secretary and Chief Compliance Officer<br class="">Gilead Sciences, Inc.</div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Paul A. Coletti</strong><br class="">Associate Patent Counsel<br class="">Johnson & Johnson</div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Erik H. Iverson, Esq.</strong><br class="">President, Business and Operations<br class="">Infectious Disease Research Institute<br class=""><strong class=""><br class="">Mr. Richard H. Kjeldgaard</strong><br class="">Consultant<br class="">Representing Pharmaceutical Research and Manufacturers of America</div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Jeffrey P. Kushan, Esq.</strong><br class="">Sidley Austin<br class="">Representing Biotechnology Industry Organization</div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Jonathan L. Marks, Esq</strong>.<br class="">Vice President, International Affairs<br class="">Generic Pharmaceuticals Association</div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">ITAC 3: Industry Trade Advisory Committee On Chemicals, Pharmaceuticals, Health/Science Products And Services</strong></div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Ms. Tiffany McCullen Atwell</strong><br class="">Director, International Government Affairs<br class="">DuPont Government Marketing and Government Affairs<br class="">E.I. du Pont de Nemours and Company</div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Mr. Harrison C. Cook</strong><br class="">Vice President, International Government Affairs<br class="">Eli Lilly and Company</div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Mr. Ralph F. Ives</strong><br class="">Executive Vice President, Global Strategy and Analysis<br class="">AdvaMed: Advanced Medical Technology Association </div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Mr. Maurice J. Kerins</strong><br class="">President<br class="">Airmed Biotech, Inc.</div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Douglas T. Nelson, Esq.</strong><br class="">Senior Advisor for Trade, Intellectual Property and Strategic Affairs<br class="">CropLife America</div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Mr. Paul A. Neureiter</strong><br class="">Executive Director, Government Affairs<br class="">Amgen Inc.</div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Mr. James R. Plante</strong><br class="">Founder and Chief Executive Officer<br class="">Pathway Genomics</div><div style="margin-top: 0.5em; margin-bottom: 0.5em; color: rgb(51, 51, 51); font-family: Arial, Verdana, sans-serif; font-size: 13px; line-height: 19.02400016784668px;" class=""><strong class="">Ms. Lisa M. Schroeter</strong><br class="">Global Director, Trade and Investment Policy<br class="">The Dow Chemical Company</div></div></body></html>